Arrhythmogenic Cardiomyopathy-Current Treatment and Future Options

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disease characterized by fibrofatty replacement of the myocardium.
• ACM can affect the right ventricle, left ventricle, or both, leading to ventricular arrhythmias (VAs) and sudden cardiac death (SCD).
• Clinical management aims to prevent SCD and manage arrhythmic events and heart failure (HF).

Purpose of the Study:

• To review current strategies for SCD prevention in ACM patients.
• To discuss the treatment of VAs and HF in ACM.
• To highlight challenges in patient selection for implantable cardioverter defibrillator (ICD) therapy.

Main Methods:

• Review of current clinical management strategies for ACM.
• Analysis of risk stratification methods including electrograms and cardiac magnetic resonance.
• Evaluation of therapeutic options such as ICDs, medical therapy, and catheter ablation.

Main Results:

• Implantable cardioverter defibrillators (ICDs) are the only proven lifesaving treatment for SCD prevention, but carry risks.
• Risk stratification relies on arrhythmic burden and ventricular dysfunction, with ECG and imaging modalities playing a role.
• Medical therapy is essential for VA treatment and preventing adverse remodeling; novel therapies' efficacy is unknown.
• Catheter ablation is effective for recurrent VAs and ICD shocks.

Conclusions:

• Effective management of ACM requires a multi-faceted approach combining device therapy, medical treatment, and potentially catheter ablation.
• Optimizing patient selection for ICDs remains a critical challenge in clinical practice.
• Further research is needed on novel therapeutic agents for ACM management.